Affordable Access

Publisher Website

Mutational analysis of transgenic mouse B cell lymphomas: indication of aTrp53-independent pathway in tumor progression

Authors
Journal
Leukemia Research
0145-2126
Publisher
Elsevier
Publication Date
Volume
23
Issue
10
Identifiers
DOI: 10.1016/s0145-2126(99)00103-4
Keywords
  • Non-Hodgkin’S Lymphoma
  • Follicular Lymphoma
  • Histologically Transformed Lymphoma
  • Tp53/Trp53Gene Mutations
  • Eμ-N-Myctransgenic Mouse Model
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Deregulated myc, bcl-2 and/or TP53 gene expression is associated with non-Hodgkin’s B cell lymphomas (B-NHLs). Eμ-N-myc transgenic mice that misexpress N-myc protein and carry a non-disrupted bcl-2 gene develop indolent B cell lymphomas reminiscent of the B-NHL, follicular lymphoma. Tumors from mice with end-stage disease exhibited discrete, nodular lesions as well as areas of diffuse tumor likely due to coalescence of enlarged follicles. Tumor DNAs were screened for mutations in the Trp53 gene, the murine homologue of the TP53 gene, which participates in B cell differentiation and survival. By PCR-based sequence analyses, we determined there were no mutations in exons 5–8, the common sites of TP53 mutation in B-NHLs. These findings suggested that disease progression in our novel murine lymphoma model may proceed via a Trp53-independent pathogenetic pathway.

There are no comments yet on this publication. Be the first to share your thoughts.